ArticleJournal of nanobiotechnology2021
Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: adaptation phenomena and cross-resistance.
Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- Design and Development of Teixobactin Analog-Loaded Magnetic Nanocomposites for Biofilm Destruction and Pathogen Elimination.Journal of functional biomaterials · 2026Article
- Viability Preservation of Probiotic Bacteria Encapsulated in Pectin-Reinforced pH-Responsive Composite Alginate Hydrogel Matrix as the Synbiotic Delivery System.Probiotics and antimicrobial proteins · 2026Article
- Article
- Nano-Modified Titanium Implant Surfaces for the Prevention and Treatment of Peri-Implantitis: A Review.International journal of nanomedicine · 2026Review
- Molecular insights into silver nanoparticle resistance in Acinetobacter baumannii and unique adaptations to ionic silver.npj antimicrobials and resistance · 2025Article
- Biosynthesized Silver Selenide Nanoparticles fromMicroorganisms · 2025Article
- Targeting ESKAPE pathogens with ZnS and Au@ZnS Core-Shell nanoconjugates for improved biofilm control.Scientific reports · 2025Article
- Silver Nanoparticles: A Versatile Tool Against Infectious and Non-Infectious Diseases.Antibiotics (Basel, Switzerland) · 2025Review
- Silver Nanoparticles as Antimicrobial Agents in Veterinary Medicine: Current Applications and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2025Review
- A Review on Risk Factors, Traditional Diagnostic Techniques, and Biomarkers for Pneumonia Prognostication and Management in Diabetic Patients.Diseases (Basel, Switzerland) · 2024Review
- E. coli and S. aureus resist silver nanoparticles via an identical mechanism, but through different pathways.Communications biology · 2024Article
- Unlocking the Potential of Silver Nanoparticles: From Synthesis to Versatile Bio-Applications.Pharmaceutics · 2024Review
- Transforming Medicine with Nanobiotechnology: Nanocarriers and Their Biomedical Applications.Pharmaceutics · 2024Review
- Silver/gold nanoalloy implant coatings with antibiofilm activityChemical communications (Cambridge, England) · 2024Article
- Coatings Based on Essential Oils for Combating Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2024Review
- Identification and florfenicol-treatment of pseudomonas putida infection in gilthead seabream (Sparus aurata) fed on tilapia-trash-feed.BMC veterinary research · 2024Article
- Advances in silver nanoparticles: a comprehensive review on their potential as antimicrobial agents and their mechanisms of action elucidated by proteomics.Frontiers in microbiology · 2024Review
- Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections.Pharmaceutics · 2023Review
- Mechanisms of Antibiotic and Biocide Resistance That Contribute toBiomedicines · 2023Review
- Development of Nanoparticle Adaptation Phenomena in Acinetobacter baumannii: Physiological Change and Defense Response.Microbiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundTreatment of bacterial biofilms are difficult and in many cases, expensive. Bacterial biofilms are naturally more resilient to antimicrobial agents than their free-living planktonic counterparts, rendering the community growth harder to control. The present work described the risks of long-term use of an important alternative antimicrobial, silver nanoparticles (NAg), for the first time, on the dominant mode of bacterial growth.
resultsNAg could inhibit the formation as well as eradicating an already grown biofilm of Pseudomonas aeruginosa, a pathogen notorious for its resilience to antibiotics. The biofilm-forming bacterium however, evolved a reduced sensitivity to the nanoparticle. Evidence suggests that survival is linked to the development of persister cells within the population. A similar adaptation was also seen upon prolonged exposures to ionic silver (Ag
conclusionThe findings signify the importance to study the nanoparticle adaptation phenomena in the biofilm mode of bacterial growth, which are apparently unique to those already reported with the planktonic growth counterparts. This work sets the foundation for future studies in other globally significant bacterial pathogens when present as biofilms. Scientifically based strategies for management of pathogenic growth is necessary, particularly in this era of increasing antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.